Cancers, Vol. 16, Pages 1288: Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts

Cancers, Vol. 16, Pages 1288: Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts Cancers doi: 10.3390/cancers16071288 Authors: Samuel J. Holzmayer Joseph Kauer Jonas Mauermann Tobias Roider Melanie Märklin B cell acute lymphoblastic leukemia (B-ALL) is characterized by an accumulation of malignant precursor cells. Treatment consists of multiagent chemotherapy followed by allogeneic stem cell transplantation in high-risk patients. In addition, patients bearing the BCR-ABL1 fusion gene receive concomitant tyrosine kinase inhibitor (TKI) therapy. On the other hand, monoclonal antibody therapy is increasingly used in both clinical trials and real-world settings. The introduction of rituximab has improved the outcomes in CD20 positive cases. Other monoclonal antibodies, such as tafasitamab (anti-CD19), obinutuzumab (anti-CD20) and epratuzumab (anti-CD22) have been tested in trials (NCT05366218, NCT04920968, NCT00098839). The efficacy of monoclonal antibodies is based, at least in part, on their ability to induce antibody-dependent cellular cytotoxicity (ADCC). Combination treatments, e.g., chemotherapy and TKI, should therefore be screened for potential interference with ADCC. Here, we report on in vitro data using BCR-ABL1 positive and negative B-ALL cell lines treated with rituximab and TKI. NK cell activation, proliferation, degranulation, cytokine release and tumor cell lysis were analyzed. In contrast to ATP site inhibitors s...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research